News & Updates

Patients with chronic hepatitis B (CHB) in the indeterminate phase are predisposed to advanced liver disease and hepatocellular carcinoma (HCC), as shown by a systematic review and meta-analysis.

Biomarker-informed molecular guidance improves anti-TNF therapy outcomes in patients with inflammatory bowel disease (IBD), increasing the likelihood of achieving disease control when compared with standard “best care,” as shown in the GUIDE-IBD trial.

The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.